Clinical Trials Logo

Myelofibrosis clinical trials

View clinical trials related to Myelofibrosis.

Filter by:

NCT ID: NCT06398457 Not yet recruiting - Multiple Myeloma Clinical Trials

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Start date: June 2024
Phase: Early Phase 1
Study type: Interventional

This research is being done to investigate the safety and effectiveness of Darzalex Faspro (daratumumab and hyaluronidase-fihj) (a monoclonal antibody that targets plasma cells that make antibodies) and whether it can lower donor specific antibodies (DSA) levels to low enough levels to permit patients to proceed with allogeneic peripheral blood transplant (alloBMT). Those being asked to participate have high DSA levels that puts those being asked to participate at high risk of rejecting the available donor's blood stem cells and making those being asked to participate ineligible to receive a stem cell transplant.

NCT ID: NCT06397313 Not yet recruiting - Myelofibrosis Clinical Trials

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

Start date: September 2024
Phase: Phase 2
Study type: Interventional

The objective of this clinical trial is to evaluate the efficacy (how well the drug works), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the study drug, RVU120, in treating adult patients with intermediate or high-risk, primary or secondary myelofibrosis. RVU120 will be given as a single agent or in combination with ruxolitinib.

NCT ID: NCT06388759 Active, not recruiting - Myelofibrosis Clinical Trials

TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients

Start date: August 1, 2022
Phase: Phase 1
Study type: Interventional

This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy of TQ05105 Tablets in patients with intermediate-risk and high-risk myelofibrosis.

NCT ID: NCT06378437 Recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of GLB-001 in Patients With Myeloid Malignancies

Start date: May 24, 2024
Phase: Phase 1
Study type: Interventional

Study GLB-001-02 is a phase 1, open-label clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of GLB-001 in study participants with relapsed or refractory or intolerant myeloid malignancies including polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), lower-risk myelodysplastic syndrome (LR-MDS), higher-risk myelodysplastic syndromes (HR-MDS), and acute myeloid leukemia (AML). This study consists of 3 parts, dose escalation (Phase 1a), dose exploration (Phase 1b) and dose expansion (Phase 1c). Dose escalation (Phase 1a) and dose exploration (Phase 1b) will evaluate the safety, tolerability, PK, PD and preliminary efficacy of GLB-001, administered orally, in study participants with PV/ET, or study participants with MF/LR-MDS/HR-MDS/AML, respectively. Dose expansion (Phase 1c) will be followed to determine the relationships among dose, exposure, toxicity, tolerability and clinical activity, to identify minimally active dose, and to select the recommended dose(s) for phase 2 study. Approximately 108 study participants may be enrolled in the study.

NCT ID: NCT06351631 Recruiting - Myelofibrosis Clinical Trials

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

Start date: May 23, 2024
Phase: Phase 3
Study type: Interventional

The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria: - Participants from the IMG-7289-202/MK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat; - Essential thrombocythemia (ET) and polycythemia vera (PV) participants from studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic remission. No hypothesis testing will be conducted in this study.

NCT ID: NCT06345495 Not yet recruiting - Myelofibrosis Clinical Trials

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

Start date: September 30, 2024
Phase: Phase 2
Study type: Interventional

To learn if giving ruxolitinib and busulfan before a stem cell transplant can help to reduce spleen size and help the transplant to succeed.

NCT ID: NCT06245941 Recruiting - Myelofibrosis Clinical Trials

A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

Start date: May 13, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open, single-arm, multi-center clinical study designed to evaluate the efficacy and safety of TQ05105 tablets combined with TQB3909 tablets in patients with moderate- and high-risk Myelofibrosis.

NCT ID: NCT06164561 Recruiting - Myelofibrosis Clinical Trials

18F-FAPI PET/MRI Imaging in Myelofibrosis: a Prospective Observational Study.

Start date: November 21, 2023
Study type: Observational

This study intends to use a prospective, observational, self-controlled, multi-center study design to evaluate the feasibility and diagnostic efficacy of 18F-FDG PET/CT and 18F-FAPI PET/MRI imaging for the evaluation of systemic fibrosis in MF patients based on the results of bone marrow pathological biopsy, and to analyze the relationship between imaging results and clinical prognosis.

NCT ID: NCT06150157 Recruiting - Neoplasms Clinical Trials

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

Start date: December 20, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D[s]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part 2 (Cohort Expansion).

NCT ID: NCT06132243 Completed - Myelofibrosis Clinical Trials

Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions

Start date: November 29, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the pharmacokinetic Characteristics of two formulations of Jaktinib Hydrochloride Tablets in Healthy Adult Volunteers